Availability

GLP-1 shortage reports

Last updated

Check reports for each medication, see affected presentations, and know when a current status cannot be confirmed. Refreshed daily.

Last checked · Nov 17, 2026 UTC
1reported in shortage
6 / 6statuses confirmed

GLP-1 medicines: the lowest self-pay prices now

  • Lowest compounded tirzepatide on a monthly plan, not FDA-approved

    Collective

    $69/mo + $199/yr membership · about $86 a month over a year with the membership · first order: membership free for the first 21 days, never charged if you cancel before

  • Lowest compounded semaglutide on a monthly plan, not FDA-approved

    Collective

    $59/mo + $199/yr membership · about $76 a month over a year with the membership · first order: membership free for the first 21 days, never charged if you cancel before

  • Lowest FDA-approved, starting dose

    LillyDirect (Eli Lilly)

    from $149/mo

  • Lowest FDA-approved injection, starting dose

    NovoCare (Novo Nordisk)

    $199/fill initially

Complete, recent FDA checks establish a shortage status for 6 of the 6 approved medications we track. 1 have a presentation reported in shortage. Check the FDA database (accessdata.fda.gov) for the latest source reports.

Active

Reported in shortage

Affected presentations from complete, recent FDA checks. National reporting does not establish stock at your pharmacy.

Liraglutide
GLP-1Victoza, Saxenda
In shortage (accessdata.fda.gov/scripts/drugshortages) (Open the FDA shortage record)
Presentation
Liraglutide, Injection, 6 mg/1 mL (NDC 0143-9144-02)
First posted
Jul 18, 2023
Updated at source
Oct 14, 2026
View FDA presentations (10)

These notices concern specific presentations, not every product containing this ingredient. A current shortage and a planned discontinuation can be reported together. FDA availability notes do not confirm local pharmacy stock.

  • Liraglutide, Injection, 6 mg/1 mL (NDC 0143-9144-02)

    In shortage
    • FDA status: Current

      Source availability: Available

      Updated at source: Oct 14, 2026

  • Liraglutide, Injection, 6 mg/1 mL (NDC 0143-9144-03)

    In shortage
    • FDA status: Current

      Source availability: Available

      Updated at source: Oct 14, 2026

  • Liraglutide, Injection, 6 mg/1 mL (NDC 0480-3667-20)

    In shortage
    • FDA status: Current

      Source availability: Available

      Distributed by Teva

      Updated at source: Sep 22, 2026

  • Liraglutide, Injection, 6 mg/1 mL (NDC 0480-3667-22)

    In shortage
    • FDA status: Current

      Source availability: Available

      Distributed by Teva

      Updated at source: Sep 22, 2026

  • Liraglutide, Injection, 6 mg/1 mL (NDC 0480-7250-46)

    Planned discontinuation
    • FDA status: To Be Discontinued

      Discontinuation of the manufacture of the drug

      Posted by FDA: May 14, 2026

      Updated at source: May 14, 2026

  • Saxenda, Injection, 6 mg/1 mL (NDC 0169-2800-15)

    In shortage
    • FDA status: Current

      Source availability: Limited Availability

      Reason: Discontinuation of the manufacture of the drug

      Product will be available until discontinuation in January 2027

      Updated at source: Sep 22, 2026

    • FDA status: To Be Discontinued

      Product will be available until discontinuation in January 2027; Discontinuation of the manufacture of the drug

      Posted by FDA: Aug 25, 2026

      Updated at source: Aug 25, 2026

  • Liraglutide, Injection, 6 mg/1 mL (NDC 71288-563-84)

    In shortage
    • FDA status: Current

      Source availability: Available

      Updated at source: Aug 27, 2026

  • Liraglutide, Injection, 6 mg/1 mL (NDC 71288-563-85)

    In shortage
    • FDA status: Current

      Source availability: Available

      Updated at source: Aug 27, 2026

  • Victoza, Injection, 6 mg/1 mL (NDC 0169-4060-12)

    In shortage
    • FDA status: Current

      Source availability: Limited Availability

      Reason: Delay in shipping of the drug

      Estimated shortage duration: TBD

      Updated at source: Sep 22, 2026

  • Victoza, Injection, 6 mg/1 mL (NDC 0169-4060-13)

    In shortage
    • FDA status: Current

      Source availability: Limited Availability

      Reason: Delay in shipping of the drug

      Estimated shortage duration: TBD

      Updated at source: Sep 22, 2026

Source: openFDA Drug Shortages (accessdata.fda.gov/scripts/drugshortages) · as of Nov 17, 2026

Full drug profile
Checked

No shortage record returned

A complete, recent FDA search returned no matching shortage records for these medications. This is not a guarantee of pharmacy stock.

SemaglutideOzempic, Wegovy, Wegovy HD, RybelsusNo shortage reported (accessdata.fda.gov/scripts/drugshortages) (Check the FDA shortage database)

No shortage is listed in the latest complete FDA check. The FDA does list discontinuation notices for specific presentations.

Last complete check: Nov 17, 2026

View FDA presentations (3)

These notices concern specific presentations, not every product containing this ingredient. A current shortage and a planned discontinuation can be reported together. FDA availability notes do not confirm local pharmacy stock.

  • Rybelsus, Tablet, 3 mg (NDC 0169-4303-30)

    Planned discontinuation
    • FDA status: To Be Discontinued

      Discontinuation of the manufacture of the drug. These products will be replaced by Ozempic (semaglutide) tablets.

      Posted by FDA: Jun 4, 2026

      Updated at source: Jun 4, 2026

  • Rybelsus, Tablet, 7 mg (NDC 0169-4307-30)

    Planned discontinuation
    • FDA status: To Be Discontinued

      Discontinuation of the manufacture of the drug. These products will be replaced by Ozempic (semaglutide) tablets.

      Posted by FDA: Jun 4, 2026

      Updated at source: Jun 4, 2026

  • Rybelsus, Tablet, 14 mg (NDC 0169-4314-30)

    Planned discontinuation
    • FDA status: To Be Discontinued

      Discontinuation of the manufacture of the drug. These products will be replaced by Ozempic (semaglutide) tablets.

      Posted by FDA: Jun 4, 2026

      Updated at source: Jun 4, 2026

TirzepatideMounjaro, ZepboundNo shortage reported (accessdata.fda.gov/scripts/drugshortages) (Check the FDA shortage database)

No matching shortage record was returned in the latest complete FDA check.

Last complete check: Nov 17, 2026

DulaglutideTrulicityNo shortage reported (accessdata.fda.gov/scripts/drugshortages) (Check the FDA shortage database)

No matching shortage record was returned in the latest complete FDA check.

Last complete check: Nov 17, 2026

ExenatideByetta (discontinued), Bydureon BCise (discontinued), Generic exenatideNo shortage reported (accessdata.fda.gov/scripts/drugshortages) (Check the FDA shortage database)

No matching shortage record was returned in the latest complete FDA check.

Last complete check: Nov 17, 2026

OrforglipronFoundayoNo shortage reported (accessdata.fda.gov/scripts/drugshortages) (Check the FDA shortage database)

No matching shortage record was returned in the latest complete FDA check.

Last complete check: Nov 17, 2026

Primary source: openFDA Drug Shortages (accessdata.fda.gov/scripts/drugshortages) · as of Nov 17, 2026

Shortage status is published by the FDA and can change daily. A drug with no reported shortage may still be constrained at an individual pharmacy, and a drug in shortage may remain dispensable in some presentations. Confirm current availability with your pharmacy.
GLPcompare is an informational data platform, not a medical provider or pharmacy. Nothing here is medical advice, a diagnosis, or a recommendation to start, stop, or change any treatment. Data is aggregated from public sources and can be incomplete or out of date. Always confirm with a licensed clinician and the current FDA label.